SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ:CYTX) (FWB:XMPA) received approvals to initiate a clinical trial in Spain to investigate the use of adipose-derived stem and regenerative cells for the treatment of cardiovascular disease. The cells will be obtained at the bedside from the patients’ own adipose (fat) tissue, the richest source of adult stem cells, and made available in real-time using Cytori’s Celution™ stem and regenerative cell processing system. Patient enrollment will begin imminently.
